| Multiple Sclerosis |
1 |
1 |
| COVID-19 |
0 |
0.99 |
| Pandemic |
0 |
0.63 |
| COVID-19 Vaccine |
0 |
0.48 |
| Antineoplastic Drug |
0 |
0.42 |
| Monoclonal Antibody |
0 |
0.42 |
| New York |
0 |
0.42 |
| Biologic Therapy |
0 |
0.98 |
| California |
0 |
0.21 |
| Clinician Health and Well-Being |
0 |
0.21 |
| Glatiramer Acetate |
0 |
0.21 |
| Grant |
0 |
0.21 |
| Immunosuppressive Therapy |
0 |
0.95 |
| Multiple Sclerosis Treatment |
0 |
0.21 |
| Medical Life |
0 |
0.08 |
| Vaccines |
0 |
0.08 |